Evelo Biosciences Analyst Ratings
Evelo Biosciences Analyst Ratings
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a maintained with a price target of $6.00 to $5.00. The current price Evelo Biosciences (EVLO) is trading at is $2.35, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/24/2022 | 112.77% | Morgan Stanley | $6 → $5 | Maintains | Equal-Weight |
| 08/15/2022 | 112.77% | Chardan Capital | $12 → $5 | Maintains | Buy |
| 11/02/2021 | 1665.96% | JMP Securities | $44 → $41.5 | Maintains | Market Outperform |
| 11/01/2021 | 410.64% | Chardan Capital | → $12 | Upgrades | Neutral → Buy |
| 06/23/2021 | 1517.02% | JMP Securities | $36 → $38 | Maintains | Market Outperform |
| 06/23/2021 | 1091.49% | Cantor Fitzgerald | → $28 | Initiates Coverage On | → Overweight |
| 05/03/2021 | 453.19% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 04/12/2021 | 665.96% | Jefferies | $11 → $18 | Upgrades | Hold → Buy |
| 01/19/2021 | 495.74% | Morgan Stanley | $6 → $14 | Maintains | Equal-Weight |
| 12/23/2020 | 1048.94% | JMP Securities | → $27 | Initiates Coverage On | → Outperform |
| 11/11/2020 | 155.32% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 05/21/2020 | 240.43% | Morgan Stanley | → $8 | Downgrades | Overweight → Equal-Weight |
| 05/12/2020 | 793.62% | BMO Capital | $24 → $21 | Maintains | Outperform |
| 05/12/2020 | 155.32% | Jefferies | $18 → $6 | Downgrades | Buy → Hold |
| 04/30/2019 | 665.96% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 01/29/2019 | 325.53% | Chardan Capital | → $10 | Initiates Coverage On | → Neutral |
| 10/12/2018 | 1176.6% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 10/11/2018 | 1176.6% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 06/04/2018 | 1134.04% | Morgan Stanley | → $29 | Initiates Coverage On | → Overweight |
| 06/04/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 06/04/2018 | 963.83% | JMP Securities | → $25 | Initiates Coverage On | → Outperform |
| 06/04/2018 | 1006.38% | BMO Capital | → $26 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2022 年 8 月 24 日 | 112.77% | 摩根士丹利 | 6 美元 → 5 美元 | 維護 | 重量相等 |
| 08/15/2022 | 112.77% | 查丹資本 | 12 美元 → 5 美元 | 維護 | 買 |
| 11/02/2021 | 1665.96% | JMP 證券 | 44 美元 → 41.5 美元 | 維護 | 市場表現跑贏大盤 |
| 11/01/2021 | 410.64% | 查丹資本 | → 12 美元 | 升級 | 中性 → 買入 |
| 06/23/2021 | 1517.02% | JMP 證券 | 36 美元 → 38 美元 | 維護 | 市場表現跑贏大盤 |
| 06/23/2021 | 1091.49% | 坎託·菲茨傑拉德 | → 28 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 05/03/2021 | 453.19% | 摩根士丹利 | 14 美元 → 13 美元 | 維護 | 重量相等 |
| 2021 年 12 月 4 日 | 665.96% | 傑富瑞集團 | 11 美元 → 18 美元 | 升級 | 持有 → 買入 |
| 01/19/2021 | 495.74% | 摩根士丹利 | 6 美元 → 14 美元 | 維護 | 重量相等 |
| 12/23/2020 | 1048.94% | JMP 證券 | → 27 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 11/11/2020 | 155.32% | 摩根士丹利 | 8 美元 → 6 美元 | 維護 | 重量相等 |
| 05/21/2020 | 240.43% | 摩根士丹利 | → 8 美元 | 降級 | 超重 → 重量相等 |
| 05/12/2020 | 793.62% | BMO Capital | 24 美元 → 21 美元 | 維護 | 跑贏大盤 |
| 05/12/2020 | 155.32% | 傑富瑞集團 | 18 美元 → 6 美元 | 降級 | 買入 → 持有 |
| 2019 年 4 月 30 日 | 665.96% | 傑富瑞集團 | → 18 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2019 年 1 月 29 日 | 325.53% | 查丹資本 | → 10 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 10/12/2018 | 1176.6% | 摩根士丹利 | 29 美元 → 30 美元 | 維護 | 超重 |
| 10/11/2018 | 1176.6% | 摩根士丹利 | 29 美元 → 30 美元 | 維護 | 超重 |
| 2018 年 4 月 6 日 | 1134.04% | 摩根士丹利 | → 29 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2018 年 4 月 6 日 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 2018 年 4 月 6 日 | 963.83% | JMP 證券 | → 25 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2018 年 4 月 6 日 | 1006.38% | BMO Capital | → 26 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
Evelo Biosciences Questions & Answers
Evelo Biosciences 問題與解答
The latest price target for Evelo Biosciences (NASDAQ: EVLO) was reported by Morgan Stanley on August 24, 2022. The analyst firm set a price target for $5.00 expecting EVLO to rise to within 12 months (a possible 112.77% upside). 4 analyst firms have reported ratings in the last year.
摩根士丹利於2022年8月24日公佈了Evelo Biosciences（納斯達克股票代碼：EVLO）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計EVLO將在12個月內升至12個月內（可能上漲112.77％）。去年有4家分析公司公佈了評級。
The latest analyst rating for Evelo Biosciences (NASDAQ: EVLO) was provided by Morgan Stanley, and Evelo Biosciences maintained their equal-weight rating.
摩根士丹利對Evelo Biosciences（納斯達克股票代碼：EVLO）的最新分析師評級由摩根士丹利提供，而Evelo Biosciences維持同等權重評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on August 24, 2022 so you should expect the next rating to be made available sometime around August 24, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Evelo Biosciences的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Evelo Biosciences的最新評級是在2022年8月24日公佈的，因此您應該預計下一個評級將在2023年8月24日左右公佈。
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a maintained with a price target of $6.00 to $5.00. The current price Evelo Biosciences (EVLO) is trading at is $2.35, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Evelo Biosciences（EVLO）評級維持不變，目標股價爲6.00美元至5.00美元。Evelo Biosciences（EVLO）目前的交易價格爲2.35美元，超出了分析師的預期區間。
